SCHEMBL2928786

SCHEMBL2928786

CN(C)C(=O)Sc1c(Cl)cc([N+](=O)[O-])cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
KMT2A Q03164 4/20 0.45
HTT P42858 2/20 0.45
GPR35 Q9HC97 1/20 0.44
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NR1H4 Q96RI1 1/20 0.38
ATM Q13315 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.36
HKDC1 Q2TB90 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11074606 0.80 PDE7A (0.51) ALDH1A1KMT2AHSD17B10GAANPC1
SCHEMBL17804010 0.78 ALDH1A1 (0.36) ALDH1A1KMT2AHTTGPR35HPGD
SCHEMBL2924582 0.76 THRB (0.39) ALDH1A1HTTHSD17B10GAAHPGD
SCHEMBL11471541 0.73 ALDH1A1 (0.59) ALDH1A1KMT2AHTTGPR35HSD17B10
SCHEMBL11079694 0.72 PDE7A (0.52) ALDH1A1KMT2AHTTGAAHPGD
SCHEMBL11339267 0.71 GAA (0.56) ALDH1A1KMT2AHTTHSD17B10GAA
SCHEMBL13116548 0.71 GAA (0.55) ALDH1A1KMT2AHTTGPR35HSD17B10
SCHEMBL6679164 0.70 HSP90AA1 (0.57) ALDH1A1KMT2AHTTGAAMEN1
SCHEMBL16698379 0.70 ALDH1A1 (0.59) ALDH1A1KMT2AHTTGPR35HSD17B10
SCHEMBL31664942 0.69 ALDH1A1 (0.48) ALDH1A1KMT2AHTTGPR35HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112805005-B Thyroxine receptor beta agonist compounds 拓臻股份有限公司 2026-05-12 CN disclosed
EP-3840755-B1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS TERNS INC (US) 2026-02-18 EP disclosed
EP-3840755-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2021-06-30 EP disclosed
CN-112805005-A Thyroxine receptor beta agonist compounds 拓臻股份有限公司 2021-05-14 CN disclosed
US-10800767-B2 Thyroid hormone receptor beta agonist compounds Terns, Inc. (US) 2020-10-13 US disclosed
US-20200062742-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. 2020-02-27 US disclosed
WO-2020041741-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS Terns, Inc. (US) 2020-02-27 WO disclosed
US-RE46024-E1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-RE46024-E1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2016-06-07 US disclosed
US-7807674-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2010-10-05 US disclosed
US-7807674-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2010-10-05 US disclosed
EP-1919878-B1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2010-09-08 EP disclosed
US-20090005383-A1 THYROID HORMONE ANALOGS HOFFMANN-LA ROCHE INC. 2009-01-01 US disclosed
US-20090005383-A1 THYROID HORMONE ANALOGS HOFFMANN-LA ROCHE INC. 2009-01-01 US disclosed
US-7452882-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2008-11-18 US disclosed
US-7452882-B2 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. (US) 2008-11-18 US disclosed
EP-1919878-A1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS F. Hoffmann-Roche AG (CH) 2008-05-14 EP disclosed
US-20070032494-A1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. 2007-02-08 US disclosed
US-20070032494-A1 Thyroid hormone analogs HOFFMANN-LA ROCHE INC. 2007-02-08 US disclosed
WO-2007009913-A1 PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062742-A1 THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS THRB, THRA, TSHR ALDH1A1 3553/4885KMT2A 3527/4885HTT 1058/4885
US-20090005383-A1 THYROID HORMONE ANALOGS THRA, THRB, TPO ALDH1A1 991/4885KMT2A 1659/4885HTT 440/4885
US-20070032494-A1 Thyroid hormone analogs THRA, THRB, TPO ALDH1A1 991/4885KMT2A 1659/4885HTT 440/4885
US-10800767-B2 Thyroid hormone receptor beta agonist compounds THRB, THRA, TSHR ALDH1A1 3553/4885KMT2A 3527/4885HTT 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.